Literature DB >> 8173767

Surfactant subtypes. In vitro conversion, in vivo function, and effects of serum proteins.

T Ueda1, M Ikegami, A Jobe.   

Abstract

Surfactant in the alveolar space can be separated into heavy and light subtypes by differential centrifugation or on isopyknic sucrose density gradients. The conversion from heavy subtypes to light subtypes occurs in vitro by surface-area cycling. However, the function of light subtypes made by cycling and substances that might influence in vitro conversion have not been evaluated. Therefore, we compared the in vivo function of the heavy and light subtypes isolated from rabbit surfactant and similar density fractions prepared in vitro by surface-area cycling. We then asked if serum, globulin, or albumin would alter the in vitro conversion. The function of surfactant fractions was studied in vivo by treating surfactant-deficient 27 d gestational age preterm rabbits with 50 mg/kg of heavy or light subtype surfactant. Dynamic compliance values and lung volumes from PV curve measurements showed that heavy subtypes had superior in vivo function compared with light subtypes independent of in vivo or in vitro sources (p < 0.01). Light subtypes prepared in vitro lost surfactant function and were similar to in vivo light forms. When serum proteins were added to the heavy subtype surfactant, the conversion rate from heavy to light subtypes was accelerated. Serum accelerated conversion more than globulin, and the serine proteinase inhibitor diisopropylfluorophosphate blocked the conversion. Albumin had no significant effect. The increased rate of conversion caused by serum identifies a new mechanism for surfactant inactivation that could occur with lung injuries associated with increased alveolar protein.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8173767     DOI: 10.1164/ajrccm.149.5.8173767

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  8 in total

1.  Surface tension in situ in flooded alveolus unaltered by albumin.

Authors:  Angana Banerjee Kharge; You Wu; Carrie E Perlman
Journal:  J Appl Physiol (1985)       Date:  2014-06-26

2.  Randomised controlled trial of colloid or crystalloid in hypotensive preterm infants.

Authors:  K W So; T F Fok; P C Ng; W W Wong; K L Cheung
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1997-01       Impact factor: 5.747

Review 3.  An overview of pulmonary surfactant in the neonate: genetics, metabolism, and the role of surfactant in health and disease.

Authors:  Paul O Nkadi; T Allen Merritt; De-Ann M Pillers
Journal:  Mol Genet Metab       Date:  2009-02-04       Impact factor: 4.797

Review 4.  Eosinophil-associated lung diseases. A cry for surfactant proteins A and D help?

Authors:  Julie G Ledford; Kenneth J Addison; Matthew W Foster; Loretta G Que
Journal:  Am J Respir Cell Mol Biol       Date:  2014-11       Impact factor: 6.914

5.  Surfactant-associated protein A is important for maintaining surfactant large-aggregate forms during surface-area cycling.

Authors:  R A Veldhuizen; L J Yao; S A Hearn; F Possmayer; J F Lewis
Journal:  Biochem J       Date:  1996-02-01       Impact factor: 3.857

Review 6.  Alveolar epithelial type II cell: defender of the alveolus revisited.

Authors:  H Fehrenbach
Journal:  Respir Res       Date:  2001-01-15

7.  The effect of titanium dioxide nanoparticles on pulmonary surfactant function and ultrastructure.

Authors:  Carsten Schleh; Christian Mühlfeld; Karin Pulskamp; Andreas Schmiedl; Matthias Nassimi; Hans D Lauenstein; Armin Braun; Norbert Krug; Veit J Erpenbeck; Jens M Hohlfeld
Journal:  Respir Res       Date:  2009-09-30

8.  Pulmonary surfactant and drug delivery: Vehiculization, release and targeting of surfactant/tacrolimus formulations.

Authors:  Alberto Hidalgo; Cristina Garcia-Mouton; Chiara Autilio; Pablo Carravilla; Guillermo Orellana; Mohammad N Islam; Jahar Bhattacharya; Sunita Bhattacharya; Antonio Cruz; Jesús Pérez-Gil
Journal:  J Control Release       Date:  2020-11-24       Impact factor: 9.776

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.